PolyNovo (ASX:PNV) has announced that its NovoSorb MTX (4 mm, 6 mm) has received TGA clearance, following the regulator's clearance of the 2 mm product in March.
The company has also entered a trading halt pending another announcement.
NovoSorb is a range of bioresorbable polymers that can be produced in many formats, including film, fibre, foam, and coatings.
NovoSorb MTX, in addition to NovoSorb BTM, offer Australian healthcare professionals versatility in the management of soft tissue defects.
NovoSorb MTX leverages the technology platform underlying NovoSorb BTM, but without a sealing membrane, and is designed to support natural wound healing, particularly for highly exudative wounds or those with an uneven wound bed.
PolyNovo chair David Williams said, “I am very happy about this, especially for plastic surgeons who sometimes need more than 2 mm to achieve effective wound management outcomes.”
Acting CEO Robyn Elliott added, “The availability of NovoSorb MTX in various thickness will provide surgeons with even more options for reconstruction of complex wounds.
